Products
Catena® is Santhera’s first product, approved under conditions in Canada for symptomatic treatment of Friedreich's Ataxia.
Learn more about the availability of Catena® outside North America
Pipeline
Santhera currently has seven clinical-stage and one late preclinical development programs with four distinct small molecules:
Catena® in Friedreich's Ataxia, Duchenne Muscular Dystrophy, Leber's Hereditary Optic Neuropathy, MELAS and Primary Progressive Multiple Sclerosis
fipamezole in Dyskinesia in Parkinson's Disease
omigapil in Congenital Muscular Dystrophy
Melanocortin-4 Receptor Antagonists (MC-4R) in Cancer Cachexia
Click on the picture to enlarge it.